Working… Menu

A Post-marketing Surveillance Study on Erbitux in Combination With Platinum-based Chemotherapy in Metastatic/Recurrent Squamous Cell Cancer of the Head and Neck

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01075841
Recruitment Status : Withdrawn (After loss of orphan drug status in Korea, study was withdrawn due to Regulatory Authority request. Patients will be enrolled into NCT01075828 instead.)
First Posted : February 25, 2010
Last Update Posted : July 2, 2014
Information provided by:
Merck KGaA, Darmstadt, Germany

No Study Results Posted on for this Study
Study was withdrawn before participants were enrolled.
Recruitment Status : Withdrawn
Actual Primary Completion Date : March 2009
Study Completion Date : No date given